Rasagiline is a monoamine oxidase-B (MAO-B) inhibitor used alone or in combination with levodopa for the treatment of Parkinson’s disease. Parkinson’s disease is a progressive neurodegenerative disorder that affects movement, leading to rigidity, tremors, and slowed physical activity. Rasagiline works by inhibiting the breakdown of dopamine in the brain, helping to improve motor symptoms. This medication is available only with a doctor's prescription and is commonly used to enhance the effects of levodopa therapy.
Parent: Rasagiline
Parent: Rasagiline
Parent: Rasagiline
Parent: Rasagiline
Parent: Rasagiline
Parent: Rasagiline
Parent: Rasagiline
Parent: Rasagiline
Parent: Rasagiline
Parent: Rasagiline
Parent: Rasagiline
Parent: Rasagiline
Parent: Rasagiline
Impurities in Rasagiline can arise due to chemical synthesis, degradation, or storage conditions. Regulatory authorities such as the FDA, EMA, and ICH enforce impurity limits to ensure drug purity, safety, and efficacy.
Process-Related Impurities
• Unreacted precursors from synthesis
• Residual solvents (e.g., methanol, ethanol, acetone)
• By-products from amide and alkylation reactions
Degradation Impurities
• Oxidation by-products due to exposure to air or light
• Hydrolysis impurities from moisture exposure
• Thermal degradation compounds under high temperatures
Elemental Impurities
• Heavy metal residues from catalysts used in synthesis
• Trace levels of lead, arsenic, cadmium, and mercury
Analytical Techniques for Impurity Detection
• High-Performance Liquid Chromatography (HPLC)
• Gas Chromatography (GC)
• Fourier-Transform Infrared Spectroscopy (FT-IR)
• Mass Spectrometry (MS)
• Rasagiline increases dopamine levels in the brain by preventing its breakdown.
• It helps reduce symptoms of Parkinson’s disease, including:
o Muscle stiffness
o Tremors
o Slowness of movement (bradykinesia)
o Difficulties with balance and coordination
• It is used alone in early-stage Parkinson’s or with levodopa in advanced stages.
• Yes, Rasagiline is a selective MAO-B inhibitor.
• It inhibits monoamine oxidase-B, an enzyme responsible for breaking down dopamine in the brain.
• By preserving dopamine, it helps improve motor control in Parkinson’s patients.
• Rasagiline does not cure Parkinson’s disease, but some studies suggest it may slow disease progression by reducing oxidative stress on neurons.
• It helps manage symptoms and may delay the need for higher doses of levodopa, which can cause motor complications.
• Rasagiline works by irreversibly inhibiting the enzyme monoamine oxidase-B (MAO-B).
• MAO-B normally breaks down dopamine in the brain; by inhibiting it, Rasagiline increases dopamine levels, improving motor function.
• Unlike non-selective MAO inhibitors, Rasagiline does not significantly affect serotonin or norepinephrine metabolism, reducing the risk of dangerous drug interactions.
